Mouth lesion injection shows promise in early trial
NCT ID NCT05327270
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This early-phase study tests whether injecting the cancer drug nivolumab directly into high-risk mouth lesions can shrink or control them. About 18 adults with biopsy-proven oral premalignant lesions will receive the injections. The goal is to see if this approach is safe and effective at reducing the risk of these lesions turning into cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.